pegylated liposome simoctocog alfa

Pegylated liposome simoctocog alfa is a long-acting, pegylated liposome conjugate of the recombinant human coagulation factor VIII simoctocog alfa, developed under the name SelectAte to improve the pharmacokinetic profile and potency of standard half‑life FVIII replacement therapy in hemophilia A.[5][7] By embedding simoctocog alfa in or associating it with PEGylated liposomes, the construct is designed to shield FVIII from immune recognition and clearance, extend circulation time, and thereby enable longer dosing intervals without increasing the FVIII dose, as explored in phase II studies where a separate injection of PEGyliposomes after standard FVIII infusions extended prophylactic dosing intervals in severe hemophilia A patients.[1][7][11] The therapeutic concept leverages PEGylated nanocarrier technology to enhance exposure and potentially reduce injection burden relative to conventional recombinant FVIII products, while maintaining FVIII’s native mechanism in the intrinsic coagulation cascade.

Other names

pegylated liposome simoctocog alfa